Human chorionic gonadotropin — LH/CG receptor agonist. Extensively studied in hypogonadism, fertility, testosterone production, and testicular function preservation.
Human chorionic gonadotropin (HCG) is a hormone naturally produced during pregnancy and has medical applications including fertility treatment and hormonal support. In research contexts, it is primarily studied for its role in stimulating testosterone production in men, supporting fertility protocols, and maintaining testicular function during or after exogenous hormone use. It is an FDA-approved prescription medication for specific medical uses.
Male Hormonal Support
HCG mimics luteinizing hormone (LH), which signals the testes to produce testosterone. In men with hypogonadism or those whose natural LH production has been suppressed, HCG is used to stimulate testicular testosterone production. It is used both as a primary treatment and to maintain testicular function alongside testosterone therapy.
Male Fertility Research
HCG is central to male fertility treatment protocols. It supports spermatogenesis by maintaining the hormonal environment within the testes needed for sperm production. Research has examined HCG protocols for men with hypogonadotropic hypogonadism and for those wanting to preserve fertility.
Female Fertility and Assisted Reproduction
HCG is used in female assisted reproduction protocols to trigger final egg maturation before retrieval. It is a well-established part of IVF and other ART protocols. The pharmacological use is based on HCG's ability to mimic the LH surge that triggers ovulation.
Effectively stimulates testosterone production in men by mimicking LH.
Maintains testicular volume and sperm production in men using testosterone therapy.
Well-established role in both male and female fertility treatment.
FDA-approved for specific medical uses including cryptorchidism in boys and fertility treatment.
HCG is a prescription medication for its FDA-approved uses — it requires medical supervision and is not a supplement. In men, HCG stimulates testosterone, estradiol, and other androgens, which means hormonal monitoring is important. The compound commonly sold under the HCG name for weight loss purposes (the 'HCG diet') is not supported by clinical evidence for weight management — randomized trials have shown no benefit over placebo for weight loss.
The pituitary gland regulates testosterone production by releasing LH, which travels through the bloodstream to the testes and tells specialized cells (Leydig cells) to produce testosterone. HCG is structurally similar enough to LH that it can activate the same receptor. When administered, HCG reaches the Leydig cells and delivers the same signal that LH would. The testes respond by producing testosterone, maintaining their normal function. This is particularly important when the pituitary is not producing enough LH — either because of a medical condition or because exogenous testosterone has signaled the pituitary to stop producing its own LH.
HCG is FDA-approved and has a well-characterized safety profile for its approved uses. In males, it can increase estradiol production alongside testosterone, which may cause gynecomastia in some men. Ovarian hyperstimulation syndrome (OHSS) is a risk in women using HCG for fertility treatment, requiring medical monitoring. As a prescription medication, appropriate dosing and monitoring by a healthcare provider are standard practice.
High Evidence
This compound has been studied in multiple large randomized controlled trials with human subjects. The evidence base is strong and consistent across independent research groups.
Published Research Ranges
250–1500 IU 2-3x weekly in published endocrinology literature
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Human Chorionic Gonadotropin and Testosterone Production in Men
A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization
Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.